首页 文献索引 SCI期刊 AI助手
登录 注册
首页 正文

Trends in pharmacological sciences. 2025 Apr 14:S0165-6147(25)00066-5. doi: 10.1016/j.tips.2025.03.009 Q113.92024

KRASG12C/mTORC1 inhibition: a powerful duo in NSCLC therapeutics

KRASG12C/mTORC1抑制在非小细胞肺癌治疗中的强强联合疗法 翻译改进

Antonios N Gargalionis  1, Kostas A Papavassiliou  2, Athanasios G Papavassiliou  3

作者单位 +展开

作者单位

  • 1 Laboratory of Clinical Biochemistry, Medical School, 'Attikon' University General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • 2 First University Department of Respiratory Medicine, 'Sotiria' Chest Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • 3 Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: papavas@med.uoa.gr.
  • DOI: 10.1016/j.tips.2025.03.009 PMID: 40234119

    摘要 中英对照阅读

    In a recent report in Nature Communications, Kitai et al. designed a combinational treatment based on targeting the active-state KRASG12C-mutant variant that characterizes a substantial subset of non-small-cell lung cancer (NSCLC) cases. The authors highlighted that dual targeting with KRASG12C (ON) and mammalian target of rapamycin (mTOR) complex (mTORC)-1-selective inhibition potentially provides a new strategy to overcome drug resistance.

    Keywords: ERK; KRAS(G12C); mTORC1; non-small-cell lung cancer.

    Keywords:KRAS G12C; mTORC1 inhibition; NSCLC

    最近,《自然通讯》上的一篇报告中,Kitai等人设计了一种基于靶向非小细胞肺癌(NSCLC)亚型中活跃状态KRASG12C-突变体的组合疗法。作者强调,通过同时使用针对KRASG12C (ON) 和哺乳动物雷帕霉素靶点 (mTOR) 复合物 1(mTORC-1)的选择性抑制剂进行双重靶向治疗,可能提供一种新的策略来克服药物耐药性。

    关键词:ERK;KRAS(G12C);mTORC1;非小细胞肺癌。

    版权所有 © 2025 Elsevier Ltd. 保留所有权利。

    关键词:KRAS G12C; mTORC1抑制; 非小细胞肺癌

    翻译效果不满意? 用Ai改进或 寻求AI助手帮助 ,对摘要进行重点提炼
    Copyright © Trends in pharmacological sciences. 中文内容为AI机器翻译,仅供参考!

    相关内容

    期刊名:Trends in pharmacological sciences

    缩写:TRENDS PHARMACOL SCI

    ISSN:0165-6147

    e-ISSN:1873-3735

    IF/分区:13.9/Q1

    文章目录 更多期刊信息

    全文链接
    引文链接
    复制
    已复制!
    推荐内容
    KRASG12C/mTORC1 inhibition: a powerful duo in NSCLC therapeutics